Suppr超能文献

石杉碱甲治疗阿尔茨海默病的研究进展

An update on huperzine A as a treatment for Alzheimer's disease.

作者信息

Little John T, Walsh Sally, Aisen Paul S

机构信息

Georgetown University Hospital, Department of Psychiatry, 3800 Reservoir Road, NW, Kober-Cogan 604, Washington, DC 20007, USA.

出版信息

Expert Opin Investig Drugs. 2008 Feb;17(2):209-15. doi: 10.1517/13543784.17.2.209.

Abstract

Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata. There is evidence that huperzine A may compare favorably in symptomatic efficacy to cholinesterase inhibitors in use. In addition, huperzine A has antioxidant and neuroprotective properties that suggest that it may be useful as a disease-modifying treatment for Alzheimer's disease (AD). The drug is available as a nutriceutical in the US. However, there have been no published controlled clinical trials outside China assessing its toxicity and efficacy. This paper reviews the development of huperzine A as a treatment for AD, including the Phase II trial now under way in the US.

摘要

石杉碱甲是一种从中国草药蛇足石杉中提取的天然胆碱酯酶抑制剂。有证据表明,石杉碱甲在症状疗效方面可能优于正在使用的胆碱酯酶抑制剂。此外,石杉碱甲具有抗氧化和神经保护特性,这表明它可能作为阿尔茨海默病(AD)的疾病修饰治疗药物有用。该药物在美国作为营养补充剂可用。然而,在中国以外没有发表过评估其毒性和疗效的对照临床试验。本文综述了石杉碱甲作为AD治疗药物的研发情况,包括美国正在进行的II期试验。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验